In a pilot study among young adults with NAFLD, our group demonstrated that physiologic GH therapy for 6 months tended to reduce hepatic lipid, with relative reduction of 36% (95% CI, −88%, 16%) in hepatic fat fraction, although these results did not achieve statistical significance [90]. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.